Literature DB >> 22123681

Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.

Jack Brown1, Kristen Brown, Alan Forrest.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of complicated bacteremia (CB) and infective endocarditis (IE). The gold standard treatment for these infections is vancomycin. A vancomycin area under the concentration-time curve from 0 to 24 h (AUC(24))/MIC ratio of >400 has been suggested as a target to achieve clinical effectiveness, and yet to date no study has quantitatively investigated the AUC(24)/MIC ratio and its association with attributable mortality (AM). We performed a review of patients treated for MRSA CB and IE from 1 July 2006 to 30 June 2008. AM was defined as deaths where CB or IE was documented as the main cause or was mentioned as the main diagnosis. Classification and regression tree analysis (CART) was used to identify the AUC(24)/MIC ratio associated with AM. Mann-Whitney and Fisher exact tests were used for univariate analysis, and logistic regression was used for multivariate modeling. The MICs were determined by Etest, and the AUC(24) was determined using a maximum a posteriori probability-Bayesian estimator. A total of 32 CB and 18 IE patients were enrolled. The overall crude mortality and AM were 24 and 16%, respectively. The CART-derived partition for the AUC(24)/MIC ratio and AM was <211. Patients with an AUC(24)/MIC ratio of <211 had a >4-fold increase in AM than patients who received vancomycin doses that achieved an AUC(24)/MIC ratio of ≥211 (38 and 8%, respectively; P = 0.02). In bivariate analysis the APACHE-II score and an AUC(24)/MIC ratio of <211 were significantly associated with AM. In the multivariate model, the APACHE-II score (odds ratio, 1.24; P = 0.04) and a vancomycin AUC/MIC ratio of <211 (odds ratio, 10.4; P = 0.01) were independent predictors of AM. In our analysis, independent predictors of AM were the APACHE-II score and an AUC(24)/MIC ratio of <211. We believe further investigations are warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123681      PMCID: PMC3264249          DOI: 10.1128/AAC.05609-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Determination of minimum inhibitory concentrations.

Authors:  J M Andrews
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

3.  Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis.

Authors:  Philippe Gilot; Gérard Lina; Thierry Cochard; Bernard Poutrel
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 4.  Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit.

Authors:  J J Schentag
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

5.  Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis.

Authors:  A J Mansur; C M Dal Bó; J T Fukushima; V S Issa; M Grinberg; P M Pomerantzeff
Journal:  Am Heart J       Date:  2001-01       Impact factor: 4.749

Review 6.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

7.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

8.  Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Christine Wennersten; Lata Venkataraman; Richard P Novick; Howard S Gold
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

9.  Vancomycin: we can't get there from here.

Authors:  Nimish Patel; Manjunath P Pai; Keith A Rodvold; Ben Lomaestro; George L Drusano; Thomas P Lodise
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

10.  Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study.

Authors:  Evelyn E Hill; Paul Herijgers; Piet Claus; Steven Vanderschueren; Marie-Christine Herregods; Willy E Peetermans
Journal:  Eur Heart J       Date:  2006-12-07       Impact factor: 29.983

View more
  29 in total

1.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

2.  Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Authors:  Evan J Zasowski; Kyle P Murray; Trang D Trinh; Natalie A Finch; Jason M Pogue; Ryan P Mynatt; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-06-01

4.  Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Authors:  D M Martirosov; M R Bidell; M P Pai; M H Scheetz; S L Rosenkranz; T P Lodise
Journal:  Diagn Microbiol Infect Dis       Date:  2017-04-02       Impact factor: 2.803

5.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.

Authors:  Michael N Neely; Lauren Kato; Gilmer Youn; Lironn Kraler; David Bayard; Michael van Guilder; Alan Schumitzky; Walter Yamada; Brenda Jones; Emi Minejima
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.

Authors:  Anthony M Casapao; Thomas P Lodise; Susan L Davis; Kimberly C Claeys; Ravina Kullar; Donald P Levine; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

7.  Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.

Authors:  Dong-Gun Lee; Yoichi Murakami; David R Andes; William A Craig
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

8.  Vancomycin AUC24 /MIC Ratio in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia.

Authors:  Misuk Ji; Hyun-Ki Kim; Soo-Kyung Kim; Woochang Lee; Heungsup Sung; Sail Chun; Mi-Na Kim; Won-Ki Min
Journal:  J Clin Lab Anal       Date:  2015-10-26       Impact factor: 2.352

Review 9.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

10.  Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.